First Time Loading...

Royalty Pharma PLC
NASDAQ:RPRX

Watchlist Manager
Royalty Pharma PLC Logo
Royalty Pharma PLC
NASDAQ:RPRX
Watchlist
Price: 28.28 USD -1.67% Market Closed
Updated: May 3, 2024

Royalty Pharma PLC
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Royalty Pharma PLC
Net Income (Common) Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Royalty Pharma PLC
NASDAQ:RPRX
Net Income (Common)
$1.1B
CAGR 3-Years
32%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Net Income (Common)
$40.6B
CAGR 3-Years
39%
CAGR 5-Years
23%
CAGR 10-Years
10%
Bristol-Myers Squibb Co
NYSE:BMY
Net Income (Common)
-$6.1B
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Net Income (Common)
$2.1B
CAGR 3-Years
-40%
CAGR 5-Years
-28%
CAGR 10-Years
-21%
Merck & Co Inc
NYSE:MRK
Net Income (Common)
$2.3B
CAGR 3-Years
-31%
CAGR 5-Years
-23%
CAGR 10-Years
-7%
Eli Lilly and Co
NYSE:LLY
Net Income (Common)
$5.2B
CAGR 3-Years
-5%
CAGR 5-Years
10%
CAGR 10-Years
1%

See Also

What is Royalty Pharma PLC's Net Income (Common)?
Net Income (Common)
1.1B USD

Based on the financial report for Dec 31, 2023, Royalty Pharma PLC's Net Income (Common) amounts to 1.1B USD.

What is Royalty Pharma PLC's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-4%

Over the last year, the Net Income (Common) growth was 2 551%. The average annual Net Income (Common) growth rates for Royalty Pharma PLC have been 32% over the past three years , -4% over the past five years .